Company intelligence / Profile preview
Multimeric Biotherapeutics, Inc.
La Jolla, California, United Statesmultimericbio.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Phase 2
01
Overview
Multimeric Biotherapeutics is developing the FortiVac vaccine platform technology that elicits strong CD8+ T cell responses. Their lead product is FortiVac-HPV to treat HPV-associated cancers. The company is in preclinical stage and seeking funding or licensing partners to advance to clinical trials.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Fusion proteinsVaccine platformProtein therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Multimeric Biotherapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Multimeric Biotherapeutics, Inc..